What the changes say
- New international and multi-jurisdiction regulatory compliance risk includes fines, license suspension, price reductions, and criminal sanctions.
- Cybersecurity risk now expressly includes incidents involving third-party information technology systems.
- Clinical-development and market-acceptance risks were substantively unchanged, with “program candidates” renamed “product candidates.”
What changed since the prior 10-K
New
- NewRisks Related to Our Business and Industry
Many of these laws provide for substantial penalties for noncompliance. The shifting regulatory environment, along with the requirement to comply with multiple jurisdictions with different compliance and/or reporting requirements, increases the possibility that a company may inadvertently run afoul of one or more laws
Changing regulations across jurisdictions could expose the company to fraud-and-abuse challenges, fines, license suspension, mandatory price reductions, or criminal sanctions.
Reworded
- 64% rewrittenRisks Related to Our Business and Industry
Legal and Regulatory Risks Related to Our Operations
Cybersecurity wording now covers incidents and disruptions involving third-party information technology systems, not just the company’s own systems.
- 33% rewrittenRisks Related to Our Business and Industry
Delays in patient enrollment may result in increased costs or may affect the timing or outcome of our planned clinical trials, which could prevent completion of these clinical trials and adversely affect our ability to advance the development of our product candidates and may result in additional net losses
The risk only changes terminology from “program candidates” to “product candidates,” without changing the clinical-trial or approval concern.
Was: Delays in patient enrollment may result in increased costs or may affect the timing or outcome of our planned clinical trials, which could prevent completion of these clinical trials and adversely affect our ability to advance the development of our program candidates and may result in additional net losses
- 27% rewrittenRisks Related to Our Business and Industry
Any of these events could prevent us from achieving or maintaining market acceptance of the particular program, if approved, and could significantly harm our business, results of operations and prospects
The risk only changes terminology from “program candidates” to “product candidates,” without changing the market-acceptance or revenue concern.
Risk factor headings as read
Headings as the filing states them, in filing order.
Risks Related to Our Business and Industry
- 01Delays in patient enrollment may result in increased costs or may affect the timing or outcome of our planned clinical trials, which could prevent completion of these clinical trials and adversely affect our ability to advance the development of our product candidates and may result in additional net losses33% rewritten
- 02Any of these events could prevent us from achieving or maintaining market acceptance of the particular program, if approved, and could significantly harm our business, results of operations and prospects27% rewritten
- 03If any product candidate is approved but does not achieve an adequate level of acceptance by physicians, hospitals, healthcare payors and patients, we may not generate sufficient revenue from these programs and may not become or remain profitable
- 04Legal and Regulatory Risks Related to Our Operations64% rewritten
- 05Many of these laws provide for substantial penalties for noncompliance. The shifting regulatory environment, along with the requirement to comply with multiple jurisdictions with different compliance and/or reporting requirements, increases the possibility that a company may inadvertently run afoul of one or more lawsNew
- 06Any cuts to Medicare reimbursement which affect our program could have a material adverse effect on our business and/or our consolidated results of operations and financial condition
Other Perspective Therapeutics 10-Ks
- FY2024 10-K risk factorsRisk factors section under review
Clinical-trial enrollment delays and unfavorable results threaten development of VMT-α-NET, VMT01, PSV359 and other candidates.
Filed Mar 26, 2025
About this page
The headings are the filing's own. The one-line readings and the overview are automated and can be wrong: read Item 1A of the 10-K for the exact wording.